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Systemic AA-amyloidosis is a complication of chronic inﬂammatory diseases and the ﬁbril protein
AA derives from the acute phase reactant serum AA. AA-amyloidosis can be induced in mice by an
inﬂammatory challenge. The lag phase before amyloid develops can be dramatically shortened by
administration of a small amount of amyloid ﬁbrils. Systemic AA-amyloidosis is transmissible in
mice and may be so in humans. Since transmission can cross species barriers it is possible that
AA-amyloidosis can be induced by amyloid in food, e.g. foie gras. In mice, development of AA-amy-
loidosis can also be accelerated by other components with amyloid-like properties. A new possible
risk factor may appear with synthetically made ﬁbrils from short peptides, constructed for tissue
repair.
 2009 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
The ﬁbril protein precursor in all forms of systemic amyloidosis
is expressed in one or several tissues, delivered to the blood plasma
and deposited in tissues often far away from the place of synthesis
[1,2]. This is a major difference from the localized amyloid forms,
e.g. those associated with type 2 diabetes or Alzheimer’s disease
where the amyloid is formed close to the place of protein synthesis
[3]. Exactly how the transport from the plasma to the deposition
site takes place is not known. Likewise, the mechanisms behind
the determination of deposition sites are almost completely
unknown.
Systemic amyloidoses are life-threatening diseases in which
one of about 15 different plasma proteins misfold and aggregate
in many different organs throughout the body [3]. Generally, there
are two known major pathways leading to the formation of the
ﬁbrils, both resulting in a concentration above the critical to favor
aggregation. In one, there is a mutation in the gene for a plasma
protein, giving rise to a destabilized protein which can create
aggregation-prone protein species. This seems to be true for thechemical Societies. Published by E
Westermark).common amyloid ﬁbril protein transthyretin and several other pro-
teins associated with familial forms of amyloidosis. In the other
way, an otherwise normal protein is over-expressed for a sufﬁ-
ciently long time to nucleate and start ﬁbrilization. This latter
route seems to be mechanism behind some of the most common
systemic amyloidoses including immunoglobulin light chain
(AL-) and AA- (reactive or secondary) amyloidoses.
The major amyloid ﬁbril protein in systemic AA-amyloidosis is
derived from an apolipoprotein called serum amyloid A (SAA).
SAA is expressed by three different genes in human [4]. Two SAA
proteins are acute phase reactants, both with the ability to form
amyloid in vivo. The third protein, SAA4, is constitutively ex-
pressed in a number of tissues and has been described to form
amyloid when mutated [5]. The two acute phase SAA proteins,
called SAA1 and SAA2 occur in several allelic forms. SAA1a seems
to be particularly common in amyloid ﬁbrils and is possibly the
most amyloidogenic species. SAA1 and SAA2 are to the major part
bound to high density lipoprotein [6] and are at healthy state only
a minor protein component. In inﬂammatory conditions the pro-
duction of SAA from the liver increases dramatically under inﬂu-
ence of interleukin (IL)-1, IL-6 and tumour necrosis factor (TNF)
and can reach plasma concentration 1000 times the normal [7].
Apolipoprotein A-I is then depleted and SAA becomes the majorlsevier B.V. All rights reserved.
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ﬁbril formation is not known.
In human, AA-amyloidosis is a complication of chronic inﬂam-
matory disorders in which the plasma SAA levels are consistently
high. Infectious disorders such as tuberculosis, leprosy or malaria
were previously the main causes and are still so in some countries
[8,9] but in theWestern world non-infectious diseases, particularly
rheumatoid arthritis, are more commonly associated with AA-
amyloidosis. Also reactive amyloidosis can be associated with
hereditary fevers, particularly familial mediterranean fever (FMF),
caused by a mutation in the MEVF gene encoding for the protein
pyrin, an IL-1beta regulator [10]. Often, many years of inﬂamma-
tory disease are necessary for amyloidosis to develop. Of yet
unknown reason only a minority of individuals with long-lasting
inﬂammations develop AA-amyloidosis. One possibility is that
these individuals have insufﬁcient degradation systems for aggre-
gated proteins. Another possibility could be that affected individu-
als have received one or several nucleation or seeding factors. This
is what the present review deals with.2. Prions
In 1957, Gajdusek and Zigas described a unique disease, affect-
ing members of the Fore people in the New Guinea Highlands [11].
The disease was progressively leading to death, usually within one
year. Extensive search for postinfectious causes, dietary deﬁciency
or toxic agents were all negative. Much in the disease, including
the restricted population in which it occurred made a heredo-
degenerative type of disorder most probable [12,13]. Autopsy
study revealed neurodegeneration and in about half of the cases
amyloid plaque-like bodies [14]. In 1966, Gajdusek et al. published
the seminal paper in which it was shown that kuru was transmis-
sible into chimpanzees by intracerebral inoculation [15]. Later, it
was shown that kuru, Creutzfeldt-Jakob diseases and scrapie, all
could be transmitted into monkeys via the food chain [16]. Ini-
tially, the transmissible material, often called scrapie agent was be-
lieved to be of viral nature and given the very long incubation time,
the name ‘slow virus’ was created. However, no virus was detected
in spite of extensive search. Intense work by Prusiner and cowork-
ers has led to convincing evidence that the infectious agent is not a
virus, but ‘protein only’ [17]. The responsible protein was identiﬁed
and given the name prion [17]. The normal prion protein, PrPC can
be converted to an abnormal, transmissible PrPSc which can start a
chain reaction by interaction with the normal protein.
3. Infectious amyloid
Interestingly, about the time when Gajdusek published the
transmission of kuru, a strange phenomenon was described in
experimental mouse AA-amyloidosis. Many strains of mice devel-
op, after a fairly long lag phase, this form of systemic amyloidosis
when given a chronic inﬂammatory challenge. Ranløv and cowork-
ers found that cells or extract from an already amyloidotic mouse
injected at the time of induction of inﬂammation dramatically
reduced this lag phase [18]. The phenomenon was veriﬁed by other
studies [19]. Initially, quite complicated extraction methods to ob-
tain AEF were used but just ordinary AA-amyloid ﬁbril prepara-
tions [20] work efﬁciently [21]. From the liver of a single
amyloidotic mouse, we made a ﬁbril extract containing 1.32 mg
protein per ml and this material is astonishingly efﬁcient at serial
dilutions down to picograms of protein [22]. The extract from this
single mouse should be enough to induce amyloidosis in millions
of animals.
The ﬁnding that formation of amyloid ﬁbrils is a nucleation
dependent event is of fundamental importance and this seems tobe principally the same for all forms of amyloid including that of
the prion protein [23]. In a solution of an amyloid ﬁbril protein
above the critical concentration a nucleus forms after a lag phase
which can be quite long. Seeding such a solution with preformed
ﬁbrils of the same nature more or less abolishes this lag phase
[23,24]. In some yet unknown way, the misfolded and aggregated
protein induces a rapid misfolding and aggregation of the protein
in solution. This in vitro phenomenon resembles what seems to
happen when an amyloid-prone animal receives AEF. Although
most data indicate that the AEF activity is exerted by the protein
core in the amyloid ﬁbril, it should be remembered that amyloid
extracts also contain some additional minor components including
serum amyloid P-component [25], proteoglycans [26] and lipids
[27]. Although these components are believed to be important in
amyloidogenesis and for the persistence of the ﬁbrils, nothing is
presently known regarding their possible role in transmission.
Studies on this possibility would be of interest.
The following experiment indicates that the seeding includes a
three-dimensional effect on the protein and shows that there is a
possibility that nucleation may originate from inorganic material
as well [28]. By heating prion-containing material above a temper-
ature where no organic material should persist, Brown et al. ob-
tained evidence that inorganic replicas formed [29]. The
infectivity of these was quite low but the ﬁnding is of great
interest.
It took quite long time until the nature of the accelerating mate-
rial in AEF was understood but today, all facts indicate that the
mechanism is seeding by ﬁbrils or ﬁbril fragments [30], similar
to the prion phenomenon [22]. This conclusion was further empha-
sized by the ﬁnding that amyloid-like ﬁbrils, made from synthetic
short peptides, exert AEF activity [31,32]. It was then shown that
the new AA-amyloid was directly added to the injected foreign ﬁ-
brils. The AEF phenomenon is not restricted to mice but has been
shown for Guinea pig [33], Chinese hamster [30] and mink [34],
indicating a general mechanism. Of great principal importance
are studies showing that murine systemic amyloidosis of a com-
pletely different biochemical form, derived from apolipoprotein
A-II, also is seedable in the same way [35,36].4. Routes for transmission of AA-amyloidosis
Prion disorders are transmissible by different routes, including
the oral way, most dramatically shown by the example of kuru
[15,37]. In most AEF-experiments, the ‘infectious’ material has
been given intravenously or intraperitoneally. However, addition
of a small amount (about 1 mg/l; calculated total dose per mouse
0.2 mg) of a ﬁbril preparation to the drinking water for 5 weeks be-
fore induction of inﬂammation accelerated the development of AA-
amyloidosis [22]. Where and how the seeding AA-amyloid ﬁbril or
particle is taken up from the gastrointestinal tract is completely
unknown. It seems possible, although unproven, that the route is
the same as for the prion seed. In the latter case, specialized epithe-
lial microfold (M) cells overlying Peyer’s patches, are believed to
play a central role [38] and may transport PrPSc transepithelially.
From there, further transport by follicular dendritic cells may take
place. Interestingly, the spleen is one organ in which PrPSc replica-
tion may occur [39] and it is also the ﬁrst organ where AA-amyloi-
dosis develops in the mouse. When radiolabelled ﬁbrils were
injected intravenously, radioactivity was particularly pronounced
in the perifollicular area in the spleen [32], the site where the very
ﬁrst amyloid develops [33]. The route for the infectious AA-mate-
rial to the spleen has not yet been clariﬁed. Further spreading
can take place by the blood since in murine AA-amyloidosis, some
circulating monocytes were found to carry amyloid ﬁbrils and had
the capability to accelerate amyloidosis in recipient animals [40].
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Acceleration of the development of AA-amyloidosis was origi-
nally described from laboratory work with mice. The question
can then be raised whether this is a type of laboratory artifact.
The fact that this kind of acceleration is efﬁcient not only in ro-
dents but also in a carnivorous animal contradicts this. Further-
more, in a recent paper the possible horizontal spreading of AA-
amyloidosis in captive cheetah was described [41]. Interestingly,
as early as 1976 and at a time when seeding of amyloid was not
known, Benditt wrote about a strange phenomenon in Peking
ducks. He pointed out that in his colony of ducks, none had devel-
oped amyloidosis after a year although two-thirds of animals of
this species in other colonies were reported to have amyloidosis
in their second year [42]. He also performed transmission experi-
ments by injection of amyloid-containing liver homogenate into
ducks and found that they in due time developed more severe
AA-amyloidosis than animals receiving liver without amyloid.
Unfortunately, no more experiments seem to have been reported.
Also in several other avian species AA-amyloidosis is common. A
few years ago, there was a mass-death of birds, particularly herring
gulls, in Southern Sweden. A number of herring gulls were ana-
lyzed and AA-amyloidosis was identiﬁed in about 50% of them
(Désirée Jansson et al., manuscript in preparation). The animals
suffered from different infections and infestation and the direct
cause of death was determined to be botulism [43]. However, the
prevalence of AA-amyloidosis was remarkable and a horizontal
transmission can be suspected but certainly not proven.6. Transmission of systemic AA-amyloidosis between species
Prion diseases can be transmitted between species, a well-
known fact since the work by Gajdusek and coworkers [15] but
particularly since the occurrence of human variant spongioform
encephalopathy (variant Creutzfeldt-Jakob disease) [44], originat-
ing from cattle and transmissible to mice [45]. Given the resem-
blance of prion protein with other amyloid ﬁbril proteins’
behavior in vitro [46], it is natural to question whether AA-amyloi-
dosis is transmissible between species. The answer is yes. As early
as 1969, Shirahama et al. reported transfer of experimental amyloi-
dosis by human splenic amyloid homogenate to mice [47]. In more
extensive studies, AA-amyloid ﬁbrils from several different mam-
malian and one avian species were found to accelerate experimen-
tal murine amyloidosis [48,49]. In our studies, we found a
considerable difference in ‘‘infectivity” between donor species
and while AA-ﬁbrils extracted from donkey were efﬁcient as amy-
loid enhancers, human AA-ﬁbrils were not (Westermark et al.,
unpublished results). Similar to the results obtained by Cui et al.
[49], we found that bovine AA-ﬁbrils have the ability to induce
AA-amyloidosis in mice. However, ﬁbrils from none of the other
tested species were as efﬁcient as those of mice in agreement of
a species barrier, similar to that described for prions [50].7. Possible inoculation in human
AA-amyloidosis occurs as a complication to chronic inﬂamma-
tory disorders. The reported incidence varies substantially be-
tween different parts of the world and only very few really
reliable studies have been reported. One major problem is that
the disease often is severely under-diagnosed. It is, however, clear
that only a proportion of individuals in the high risk zone develop
AA-amyloidosis and the reason for this is unknown. One possibil-
ity is that AA-amyloidosis develops as a result of a stochastic
event, similar to what has been proposed for sporadic Creutz-
feldt-Jakob disease. However, there is a deﬁnite possibility thatat least in some cases, the disease is induced by a seeding agent.
Direct seeding with amyloid ﬁbrils from another individual is pos-
sible, but probably rare. However, Sponarova et al. [40] found in
amyloidotic mice scattered monocytes, containing deﬁnite AA-
amyloid particles. Such cells were able to transmit AA-amyloidosis
to recipient mice. Furthermore, blood cells from humans with AA-
amyloidosis but not healthy individuals accelerated AA-amyloido-
sis in mice (G.T. Westermark et al., to be published). Transmission
of variant, but not classical, Creutzfeldt-Jakob disease via blood
transfusion has occurred [51–53]. A transfer of AA-ﬁbrils by trans-
fusion is theoretically quite possible. Organ transplantation is an-
other risk factor as shown by us [54]. A third, possible route of
transmission of AA-amyloidosis could be by heterologous seeding.
Systemic AA-amyloidosis is common in many mammalian and
avian species and may enter our food chain. Thus, Tojo et al. found
a high incidence of AA-amyloidosis in slaughtered Japanese cows
[55]. This form of amyloidosis is particularly common in several
species of birds and is a problem in duck and goose industry.
AA-amyloid was found in commercially available duck liver and
in paté de foie gras [56] and ﬁbrils from such material accelerated
amyloidosis in mice over-expressing IL-6, both when administered
intravenously and given orally [56]. Similar to the situation with
bovine spongioform encephalopathy where a large human popula-
tion is believed to have ingested infected meat from such animals,
it is very likely that many, perhaps a majority of individuals in
many countries have eaten food containing AA-amyloid ﬁbrils
which may, if the conditions are the right, induce amyloidosis in
the recipient.
One interesting phenomenon, noted in the mouse, is that there
may be a long delay between the intake of amyloid enhancing
material and the development of disease. When amyloid ﬁbrils
were given intravenously into animals without an inﬂammatory
challenge, the mice stayed healthy. However, if inﬂammation
was induced with silver nitrate as much as 4 months later, amyloi-
dosis developed almost immediately [22]. That means the individ-
uals may be primed for the amyloid disease in the case that a
chronic inﬂammatory disease is acquired later. A similar primed
state has been described in murine AA-amyloidosis after resolution
of the deposits [57]. It will be very difﬁcult to prove an association
of ingestion of amyloid and development of AA-amyloidosis if this
kind of delayed effect is true also in human. It is of interest to note
that the incubation period for kuru has been proven to be as long
as over 50 years [58].8. Additional amyloid induction possibilities
Not only amyloid ﬁbrils may induce AA-amyloidosis in suscep-
tible animals. There are many examples of amyloid-like protein
assemblies in nature. Spider silk contain beta-sheet ﬁbrils [59]
and ﬁbrils of the prion-like Saccharomyses protein Sup35 [60]
and bacterial curli [61] have typical amyloid ﬁbril properties. Silk
[62,63], curli, and Sup35 ﬁbrils [63], all have AEF properties in
the mouse model. One line in nano-technology for tissue engineer-
ing includes construction of a ﬁbrillar scaffold, made from assem-
bled short synthetic peptides [64,65]. Such ﬁbrils forming
hydrogels have a great potential to provide a scaffold for new tis-
sue to grow on. They can have great advantages over some other
synthetic materials, for example they are biodegradable. There
are different ways to construct the materials and one is through
the assembly of peptides to beta-sheet ﬁbrils. These are ultrastruc-
turally amyloid-like, bind Congo red and show green birefringence
after this staining. Interestingly, such intentionally amyloid-like ﬁ-
brils may accelerate systemic AA-amyloidosis in the mouse (Wes-
termark et al., submitted manuscript). This should be a concern
given the purpose to use the assembled peptides in vivo. Methods
Fig. 1. A possible strain phenomenon in systemic AA-amyloidosis. In a and b is shown a section of a kidney with widely spread deposits in glomeruli (arrows). There is also
amyloid in arterioli. The section in c and d is from a kidney with almost no amyloid in the glomeruli (arrows) but pronounced vascular amyloidosis. Congo red with normal
light in a and c and polarized light in b and d.
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constructed for in vivo use obviously have to be developed.
Taken together, these different facts show that we in the natural
and cultural environment are surrounded by and probably ingest
and inhale many different protein assemblies which may start a
systemic AA-amyloidosis in a susceptible individual, i.e. any with
a long-lasting inﬂammation leading to persistently high plasma
concentration of SAA. Humans are probably not as sensitive as
the experimentally used mouse strains and more rarely are the
SAA levels in humans persistently as high as those reached in the
laboratory animals. In addition, there is nothing known about bar-
riers between other animals and human. We may also have protec-
tion systems against aggregation of proteins into amyloid ﬁbrils,
including immunity [66] (Nyström et al., submitted manuscript).
Finally, one may speculate whether seeding with foreign materials
may play a role in the pathogenesis of other amyloid-related
disorders.
9. Variations in systemic AA-amyloidosis – a strain
phenomenon?
Most commonly, human AA-amyloid is derived from one single
gene product, SAA1a [67,68]. In spite of this, the disease is not uni-
form. Interestingly, there are at least two distinctive phenotypes,
particularly well recognized in the kidney [69–71]. In the most
common, glomeruli are severely affected (Fig. 1a and b), resulting
in early proteinuria. In the other type, there is massive vascular
amyloidosis but very little glomerular deposits (Fig. 1c and d)
and patients with this form may present with renal insufﬁciency
without glomerular leakage. The two histological types are
strongly associated with protein cleavage pattern [71,72] and par-
ticularly long and short AA-proteins are characteristic of the vascu-
lar type. These two morphological variants have also different
staining properties. It should be pointed out that in these patients
amyloid deposits at other locations, e.g. spleen and liver are iden-
tical with that in the kidneys. The reason for this variation is com-
pletely unknown but may be related to the strain phenomenon in
prion diseases. It has been known for long time that prions mayvary in their incubation time and in their electrophoretic behavior
after proteinase K digestion. These differences in properties can be
propagated repeatedly in mice with identical prion genes. In vitro
experiments with recombinant truncated prion proteins have con-
vincingly shown that the propagation is conformational driven by
conformation templating, i.e. the protein adapts the three dimen-
sional structure of the seed [73,74]. The generated ﬁbrils acquired
similar secondary structure and morphology as the seed. Similar
results have been obtained with the Saccharomyces prion protein
Sup35, a protein that has no sequence identity with the mamma-
lian prion protein but which can aggregate into amyloid-like ﬁbrils
[75,76]. These similar ﬁndings with two completely unrelated pro-
teins making amyloid-like ﬁbrils can point to a universal mecha-
nism which may be attributable to human amyloid forms of
other protein nature, including systemic AA-amyloidosis. If this
holds true, we should expect differences in ﬁbril morphology in
experimental amyloidosis obtained with different seed. However,
this possibility seems not to have been studied as yet but is a sub-
ject of our laboratories.
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